

## Week Gone


- ⇒ In the week ended on Friday, 30 April 2021, the Sensex jumped 903.91 points or 1.89% to settle at 48,782.36. The Nifty 50 index advanced 289.75 points or 2.02% to settle at 14,631.10.
- ⇒ The BSE Mid-Cap index rose 359.01 or 1.80% to settle at 20,312.20. The BSE Small-Cap index surged 665.10 points or 3.17% to settle at 21,670.11.
- ⇒ Japan's retail sales rose 5.2% in March as compared with a year ago, according to government data.

## Week Ahead

- ⇒ Auto stocks will be in focus as auto companies will start announcing monthly sales numbers for April starting from 1 May 2021.
- ⇒ In economic data, Markit Manufacturing PMI for April will be declared on 3 May 2021. Markit Services PMI for April will be declared on 5 May 2021.

## Technical Overview

Index closed with a gain of 2.02% at 14631. Index opened this week with gap up and remained strong for first half of the week while later in last 2 days witness profit booking and erased some of its early gains. Going ahead index has a support around 14450, sustenance below the same will open the way for 14350-14200 levels. While on the higher side the resistance is visible around 14750-14830-14950.



Source: Falcon, BP Equities Research

## Weekly Wealth

## DOMESTIC INDICES

Index	30-Apr-21	23-Apr-21	Weekly % Chg
Nifty	14,631	14,341	2.0
Nifty Next 50	34,759	34,285	1.4
Nifty 100	14,791	14,511	1.9
Nifty 500	12,364	12,106	2.1
Nifty Midcap 100	24,196	23,493	3.0
Sensex	48,782	47,878	1.9
BSE 100 Index	14,834	14,533	2.1
BSE 200 Index	6,299	6,172	2.1
BSE 500 Index	19,690	19,271	2.2
BSE Mid-Cap	20,312	19,953	1.8
BSE Small Cap	21,670	21,005	3.2

## NIFTY TOP GAINERS (WEEKLY)

Scrip	30-Apr-21	23-Apr-21	Weekly % Chg
Bajaj Finance L	5,451.9	4,667.8	16.8
JSW Steel	717.9	635.4	13.0
Tata Steel	1,034.0	925.6	11.7
Bajaj Finserv Ltd.	11,041.7	9,916.7	11.3
IndusInd Bank	935.0	850.0	10.0

## NIFTY TOP LOSERS (WEEKLY)

Scrip	30-Apr-21	23-Apr-21	Weekly % Chg
HCL Tech	899.0	955.7	-5.9
Britannia Inds	3,449.0	3,650.3	-5.5
Maruti Suzuki	6,455.7	6,676.1	-3.3
Mahindra & Mahindra	752.6	777.9	-3.2
HDFC	2,420.1	2,497.4	-3.1

## WORLD INDICES

Index	30-Apr-21	23-Apr-21	Weekly % Chg
Nikkei Index	28,813	29,021	-0.7
Hang Seng Index	28,725	29,079	-1.2
Kospi Index	3,148	3,186	-1.2
Shanghai SE Composite	3,447	3,474	-0.8
Strait Times Index	3,218	3,194	0.8
Dow Jones	34,060	33,746	0.9
NASDAQ	14,083	13,888	1.4
FTSE	6,971	6,907	0.9

## FOREX

Currency	30-Apr-21	23-Apr-21	Weekly % Chg
US\$ (Rs.)	74.1	75.0	-1.1
GBP (Rs.)	103.0	103.9	-0.8
Euro (Rs.)	89.5	90.4	-1.1
Yen (Rs.) 100 Units	68.0	70.0	-2.9

## FII - ACTIVITY

(Rs. Cr.)

Date	Purchases	Sales	Net
30-Apr-21	7,951.1	11,416.1	-3,465.1
29-Apr-21	6,399.3	5,590.0	809.4
28-Apr-21	7,822.6	7,056.5	766.0
27-Apr-21	5,527.8	6,982.5	-1,454.8
26-Apr-21	7,660.7	8,772.6	-1,111.9
<u>MTD</u>	133795.8	145835.2	-12039.4


## DII - ACTIVITY

(Rs. Cr.)

Date	Purchases	Sales	Net
30-Apr-21	5,761.8	4,342.5	1,419.3
29-Apr-21	4,222.3	5,164.6	-942.4
28-Apr-21	6,349.2	5,913.0	436.2
27-Apr-21	6,484.7	5,021.3	1,463.4
26-Apr-21	6,518.0	5,495.5	1,022.6
<u>MTD</u>	97884.6	86524.7	11359.9

# Weekly Wealth

## BSE WEEKLY SECTORAL PERFORMANCE



Source: BSE, BP Equities Research

### TOP OPEN INTEREST GAINERS (WEEKLY)

SCRIP NAME	30-Apr-21	23-Apr-21	Weekly % Chg	30-Apr-21	23-Apr-21	Weekly % Chg
	Share Price (Rs.)			Open Interest		
ADANI PORTS	735.1	726.0	1.3	71716250	24870000	188.4
GRASIM	1408.0	1280.5	10.0	14118425	7849850	79.9
APLLTD	992.2	1000.3	-0.8	1178650	659450	78.7
JSWSTEEL	721.35	634.95	13.6	33583950	20228400	66.0
ESCORTS	1126.45	1138	-1.0	3165250	1987700	59.2

### TOP OPEN INTEREST LOSERS (WEEKLY)

SCRIP NAME	30-Apr-21	23-Apr-21	Weekly % Chg	30-Apr-21	23-Apr-21	Weekly % Chg
	Share Price (Rs.)			Open Interest		
TATACONSUM	670.75	665.05	0.9	6813450	16699500	-59.2
MPHASIS	1767.95	1696.65	4.2	247325	417300	-40.7
GAIL	138	129.75	6.4	31671200	47872800	-33.8
CUMMINSIND	838.8	851.75	-1.5	1010400	1477200	-31.6
MINDTREE	2115.55	2021.15	4.7	1488000	2160800	-31.1

#### Company Background

Fortis Healthcare Limited is an integrated healthcare delivery service provider. The Company is engaged in establishing, maintaining, operating, running, managing or administering hospitals, medicine, healthcare, diagnostic, health aids and research centers. It operates through the Clinical Establishments Division and the Medical Services Division. The Clinical Establishments Division owns, maintains and operates clinical establishments (being fully air-conditioned institutions established, and specifically customized and duly fitted with all fixtures, fittings, certain medical equipment and infrastructure required for running and operating the hospitals), as well as provides services under outpatient division and radio-diagnostic services. The Medical Services Division undertakes the business of running the hospital operations, including in-patient services and emergency services. The Company operates its healthcare delivery services in India, Dubai, Mauritius and Sri Lanka.

#### Investment Rationale

##### Established position in Healthcare segment

Fortis Healthcare provides services with 27 hospitals (including 4 network hospitals) present across the domestic country which includes states like Haryana Punjab, Delhi; Shalimar Bagh, Bengaluru, and Mumbai. These hospitals offer world-class services and attract international patients as well. SRL (owned by fortis) has been a strong brand in both retail and business to business (B2B) diagnostics, managing over 400 labs (including joint ventures) with over 1,400 collection centres and over 7,000 sample pick-up points in India.

##### Strategic tie-ups to leverage the operational performance

Integrated Healthcare a holdings (IHH) owns and operates one of the largest hospital networks globally and has an established track record of acquiring and successfully running large healthcare facilities across multiple countries. IHH has already acquired surplus stake in Fortis Group in FY18 which has helped to reduce high-cost debt and buy RHT health trust assets. This led to significant improvement in cash accrual and strengthening of the financial risk profile. Therefore, such strategic partnership will enable to leverage its operational efficiency in, offsetting long term debts and uncertain headwinds in future.

#### Valuation and Outlook

Fortis healthcare Ltd has a long and established track record in the healthcare sector in India and a large and established network of healthcare facilities provides an edge among its competitors. Moreover, its presence across various healthcare verticals, including secondary, tertiary and diagnostics with affordability, widening medical insurance coverage, and growing healthcare awareness will help to create business sustainability. On the valuation front, we have valued the company based on the SOTP method and recommend a BUY rating on this stock with a price target of INR 256 (22% upside from CMP) with a 12 months investment horizon.

#### Stock Rating

BUY	HOLD	SELL
> 15%	-5% to 15%	< -5%

#### Sector Outlook

Positive

#### Stock

CMP (INR)	211
Target Price (INR)	256
NSE Symbol	FORTIS
BSE Code	532843
Bloomberg	FORH IN
Reuters	FOHE BO


#### Key Data

Nifty	14,341
52WeekH/L(INR)	228/113.
O/s Shares (Mn)	755
Market Cap (INR bn)	159
Face Value (INR)	10

#### Average volume


3 months	49,28,030
6 months	41,57,910
1 year	30,31,000

#### Share Holding Pattern (%)



■ Promoters ■ FII ■ DII ■ Others

#### Relative Price Chart



# Weekly Wealth

## Key Financials

YE March (INR Mn)	FY19	FY20	FY21E	FY22E	FY23E
<b>Revenue</b>	<b>44,694</b>	<b>46,323</b>	<b>47,203</b>	<b>49,564</b>	<b>53,529</b>
<i>Revenue Growth (Y-o-Y)</i>	-2.0%	3.6%	1.9%	5.0%	8.0%
<b>EBIDTA</b>	<b>2,252</b>	<b>6,095</b>	<b>3,965</b>	<b>8,079</b>	<b>9,314</b>
<i>EBIDTA Growth (Y-o-Y)</i>	-17.5%	170.6%	-34.95%	103.75%	15.29%
<b>Net Profit</b>	<b>(2,989)</b>	<b>579</b>	<b>(1,416)</b>	<b>2,577</b>	<b>3,426</b>
<i>Net Profit Growth (Y-o-Y)</i>	-70.4%	19.4%	-344.4%	182.0%	32.9%
<b>Diluted EPS</b>	<b>-4.0</b>	<b>0.8</b>	<b>-1.9</b>	<b>3.4</b>	<b>4.5</b>
<i>Diluted EPS Growth (Y-o-Y)</i>	-70.4%	-119.4%	-344.4%	-282.0%	32.9%

## Key Ratios

<b>EBIDTA margin (%)</b>	<b>5.0%</b>	<b>13.2%</b>	<b>8.4%</b>	<b>16.3%</b>	<b>17.4%</b>
NPM (%)	-6.7%	1.3%	-3.0%	5.2%	6.4%
<b>RoE (%)</b>	<b>-8.8%</b>	<b>1.7%</b>	<b>-4.3%</b>	<b>7.2%</b>	<b>8.8%</b>
RoCE (%)	4.7%	12.5%	8.3%	16.1%	17.4%

## Valuation Ratios

<b>P/E (x)</b>	<b>-53.0x</b>	<b>273.6x</b>	<b>-112.0x</b>	<b>61.5x</b>	<b>46.3x</b>
EV/EBITDA	76.7x	28.3x	43.6x	21.4x	18.5x
<b>P/BV (x)</b>	<b>4.7x</b>	<b>4.6x</b>	<b>4.8x</b>	<b>4.5x</b>	<b>4.1x</b>
Market Cap. / Sales (x)	3.5x	3.4x	3.4x	3.2x	3.0x

Source: Company, BP Equities Research



Research Desk

Tel: +91 22 61596406

Institutional Sales Desk

Tel: +91 22 61596403/04/05

Disclaimer Appendix

**Analyst (s) holding in the Stock : Nil****Analyst (s) Certification:**

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

**General Disclaimer**

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

Recipients of this material should rely on their own investigations and take their own professional advice. BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

**Corporate Office:**

4th floor,  
Rustom Bldg,  
29, Veer Nariman Road, Fort,  
Mumbai-400001  
Phone- +91 22 6159 6464  
Fax-+91 22 6159 6160  
Website- [www.bpwealth.com](http://www.bpwealth.com)

**Registered Office:**

24/26, 1st Floor, Cama Building,  
Dalal street, Fort,  
Mumbai-400001  
BP Wealth Management Pvt. Ltd.  
CIN No: U67190MH2005PTC154591  
BP Equities Pvt. Ltd.  
CIN No: U67120MH1997PTC107392